Cardiac Valve Complications in Prolactinomas Treated With Cabergoline (ValveCab)
Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline
Sponsor: Federico II University
Listed as NCT00460616, this observational or N/A phase trial focuses on Prolactinomas and remains completed. Sponsored by Federico II University, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Jan 2017 — Apr 2018 [monthly]
Completed PHASE4
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Federico II University
For direct contact, visit the study record on ClinicalTrials.gov .